CD20 therapy, CD22 therapy and combined treatment of CD19 by cell expressing chimeric antigen receptor (car)

• 1. CD20疗法、CD22疗法和与CD19嵌合抗原受体(CAR)表达细胞的联合疗法 [P] . 中国专利： CN108350058A . 2018-07-31
• 2. 表达CD19和CD20抗体基因嵌合抗原受体T细胞的转化及扩增培养与保存方法 [P] . 中国专利： CN106701827A . 2017-05-24
• 3. Combined therapy with CD20 therapy, CD22 therapy and CD19 chimeric antigen receptor (car) expressing cells [P] . JP6961490B2 . 2021-11-05

  机译： 结合治疗CD20疗法，CD22治疗和CD19嵌合抗原受体（轿车）表达细胞

• 4. CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 [P] . RU2752918C2 . 2021-08-11

  机译： CD20疗法，CD22治疗和表达嵌合抗原受体（轿车）K CD19的细胞组合治疗

• 5. CD20 therapy, CD22 therapy, and combination therapy with CD19 chimeric antigen receptor (CAR) expressing cells [P] . 日本专利： JP2018518939A . 2018-07-19

  机译： CD20治疗，CD22治疗以及CD19嵌合抗原受体（CAR）表达细胞的联合治疗

• 1. Relevant nursing measures for the adverse reactions associated with chimeric antigen receptor T cells (CAR-T) immunotherapy: a systematic review of case reports [J] . Xu Zhang, Di Sun, Gui-Chun Jiang 护理前沿（英文） . 2019,第002期
• 2. Relevant nursing measures for the adverse reactions associated with chimeric antigen receptor T cells (CAR-T) immunotherapy: a systematic review of case reports? [J] . Xu Zhang, Di Sun, Gui-Chun Jiang 护理研究（英文版） . 2019,第002期
• 3. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo [J] . Xiaojun Tang, Yan Zhou, Wenjie Li, 生物医学研究杂志（英文版） . 2014,第006期
• 4. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo [J] . Xiaojun Tang, Yan Zhou, Wenjie Li, 生物医学研究杂志：英文版 . 2014,第006期
• 5. Main Issues and Current Strategies in Enhancing the Efficacy of Chimeric Antigen Receptor T-Cell Therapy among Tumor Treatments [C] . Zhengting He International Conference on Frontiers of Biological Sciences and Engineering . 2020
• 6. Targeting the Disialoganglioside GD2 with Chimeric Antigen Receptor T Cells for Immunotherapy in Diffuse Midline Gliomas, and Exploration of Neuron-OPC Synaptic Connectivity in the Context of Adaptive Myelination [D] . Mount, Christopher W. 2020
• 7. A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia [O] . Yiyun Wang, Yingying Yang, Ruimin Hong, 2020
• 8. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells [O] . Eugenia Zah, Meng-Yin Lin, Anne Silva-Benedict, 2016

• 1. Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non- Hodgkin lymphoma: A case report [J] . Zhi-Yun Niu ,Li Sun ,Shu-Peng Wen . 世界临床病例杂志 . 2021,第010期
• 2. 靶向CD19嵌合抗原受体T细胞治疗难治复发弥漫大B细胞淋巴瘤获快速缓解伴迟发性肠穿孔 [C] . 胡永仙 ,吴昭 ,魏国庆 . 2017中国血液学大会 . 2017
• 3. 抗CD19和CD22嵌合抗原受体T细胞的构建及在B系肿瘤中的联合应用 [A] . 赵磊 . 2019